Is glucagon-like peptide 1 receptor analogues effective and safe in severe COVID-19 patients with type 2 diabetes?-a case report.

Many cases of novel coronavirus 2019 (COVID-19) have confirmed in many countries around the world. Due to the disorders of the immune system, diabetic patients are more likely to suffer from severe COVID-19. Glucagon-like peptide 1 receptor analogues (GLP-1R analogues) commonly can be used to reduce blood sugar. There is no clear evidence that it can be safely and effectively used in patients with diabetes merged severe COVID-19. In this case, we described A 65-year-old male with hypertension and diabetes was diagnosed with severe COVID-19, he took liraglutide at doses ranging from 0.8 to 1.8 mg. Before admission, liraglutide was not used to reduce blood glucose. Hydroxychloroquine sulfate and abidol were used to antivirus and supportive treatment were used simultaneously during hospitalization. During treatment, the patient's own state was paid attention to, and blood glucose, liver function, kidney function, white blood cells, lymphocytes and other indicators were checked and chest CT was reviewed regularly, which could reflect changes in disease. After treatment, the patient's blood glucose was under control, and his liver function, renal function, white blood cells, lymphocytes and other indicators were normal and chest CT also improved. The case showed that liraglutide may be effective and safe used in patients with severe COVID-19 combined with type 2 diabetes, but more clinical trials are needed.